1. Home
  2. ELTX vs BARK Comparison

ELTX vs BARK Comparison

Compare ELTX & BARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$3.04

Market Cap

81.2M

Sector

Health Care

ML Signal

HOLD

Logo BARK Inc.

BARK

BARK Inc.

HOLD

Current Price

$10.29

Market Cap

92.7M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELTX
BARK
Founded
2011
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Department/Specialty Retail Stores
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
81.2M
92.7M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
ELTX
BARK
Price
$3.04
$10.29
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
$18.00
$37.50
AVG Volume (30 Days)
269.9K
51.7K
Earning Date
05-12-2026
06-03-2026
Dividend Yield
N/A
N/A
EPS Growth
39.29
N/A
EPS
N/A
0.08
Revenue
$2,301,000.00
$394,843,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.43
P/E Ratio
N/A
$130.13
Revenue Growth
N/A
N/A
52 Week Low
$2.66
$0.50
52 Week High
$16.00
$11.32

Technical Indicators

Market Signals
Indicator
ELTX
BARK
Relative Strength Index (RSI) 41.08 52.10
Support Level $2.72 $8.49
Resistance Level $3.28 $10.94
Average True Range (ATR) 0.17 0.61
MACD 0.12 0.02
Stochastic Oscillator 51.24 44.00

Price Performance

Historical Comparison
ELTX
BARK

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

About BARK BARK Inc.

BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.

Share on Social Networks: